VYNE THERAPEUTICS INC (VYNE) Stock Price, Quote, News and Overview
NASDAQ:VYNE - Nasdaq - US92941V3087 - Common Stock - Currency: USD
VYNE Quote, Performance and Key Statistics
1
-0.04 (-3.85%)
The current stock price of VYNE is 1 USD. In the past month the price decreased by -30.56%. In the past year, price decreased by -60.63%.
VYNE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 52.7 | 687.32B | ||
| JNJ | JOHNSON & JOHNSON | 15.25 | 368.73B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 19.68 | 312.99B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.62 | 223.60B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.13 | 220.00B | ||
| MRK | MERCK & CO. INC. | 9.96 | 194.83B | ||
| PFE | PFIZER INC | 7.36 | 134.23B | ||
| SNY | SANOFI-ADR | 11.83 | 127.50B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.39 | 95.42B | ||
| GSK | GSK PLC-SPON ADR | 8.86 | 80.03B | ||
| ZTS | ZOETIS INC | 27.62 | 74.02B | ||
| HLN | HALEON PLC-ADR | 22.92 | 50.57B |
Related stock screener links
About VYNE
Company Profile
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 13 full-time employees. The company went IPO on 2018-01-25. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Company Info
VYNE THERAPEUTICS INC
685 Route 202/206 N., Suite 301
Bridgewater NEW JERSEY 08807 US
CEO: David Domzalski
Employees: 13
Phone: 18007757936
VYNE THERAPEUTICS INC / VYNE FAQ
What is the stock price of VYNE THERAPEUTICS INC today?
The current stock price of VYNE is 1 USD. The price decreased by -3.85% in the last trading session.
What is the ticker symbol for VYNE THERAPEUTICS INC stock?
The exchange symbol of VYNE THERAPEUTICS INC is VYNE and it is listed on the Nasdaq exchange.
On which exchange is VYNE stock listed?
VYNE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VYNE THERAPEUTICS INC stock?
10 analysts have analysed VYNE and the average price target is 6.5 USD. This implies a price increase of 550.25% is expected in the next year compared to the current price of 1. Check the VYNE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VYNE THERAPEUTICS INC worth?
VYNE THERAPEUTICS INC (VYNE) has a market capitalization of 16.66M USD. This makes VYNE a Nano Cap stock.
How many employees does VYNE THERAPEUTICS INC have?
VYNE THERAPEUTICS INC (VYNE) currently has 13 employees.
What are the support and resistance levels for VYNE THERAPEUTICS INC (VYNE) stock?
VYNE THERAPEUTICS INC (VYNE) has a resistance level at 1.15. Check the full technical report for a detailed analysis of VYNE support and resistance levels.
Is VYNE THERAPEUTICS INC (VYNE) expected to grow?
The Revenue of VYNE THERAPEUTICS INC (VYNE) is expected to decline by -62.5% in the next year. Check the estimates tab for more information on the VYNE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VYNE THERAPEUTICS INC (VYNE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VYNE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VYNE, evaluating the profitability, health, valuation and growth aspects
- VYNE THERAPEUTICS INC (VYNE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VYNE THERAPEUTICS INC (VYNE) Sales and EPS estimates to see what analysts future expectations are.
- VYNE THERAPEUTICS INC (VYNE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VYNE THERAPEUTICS INC (VYNE) Insider and Institutional Ownership to learn about the owners and their transactions.
- VYNE THERAPEUTICS INC (VYNE) Stock Chart to make your own analysis
- VYNE THERAPEUTICS INC (VYNE) Latest news and press-releases to stay up to date.
Does VYNE THERAPEUTICS INC (VYNE) stock pay dividends?
VYNE does not pay a dividend.
When does VYNE THERAPEUTICS INC (VYNE) report earnings?
VYNE THERAPEUTICS INC (VYNE) will report earnings on 2025-08-12.
What is the Price/Earnings (PE) ratio of VYNE THERAPEUTICS INC (VYNE)?
VYNE THERAPEUTICS INC (VYNE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.99).
What is the Short Interest ratio of VYNE THERAPEUTICS INC (VYNE) stock?
The outstanding short interest for VYNE THERAPEUTICS INC (VYNE) is 1.59% of its float. Check the ownership tab for more information on the VYNE short interest.
VYNE Technical Analysis
VYNE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VYNE. VYNE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
VYNE Financial Highlights
Over the last trailing twelve months VYNE reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 81.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -59.54% | ||
| ROE | -76.48% | ||
| Debt/Equity | 0 |
VYNE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to VYNE. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of -33.83% and a revenue growth -62.5% for VYNE